CA3197104A1 - Bifunctional antagonists of activin/tgf-beta and rankl and uses thereof - Google Patents

Info

Publication number

CA3197104A1

CA3197104A1 CA3197104A CA3197104A CA3197104A1 CA 3197104 A1 CA3197104 A1 CA 3197104A1 CA 3197104 A CA3197104 A CA 3197104A CA 3197104 A CA3197104 A CA 3197104A CA 3197104 A1 CA3197104 A1 CA 3197104A1

Authority

CA

Canada

Prior art keywords

seq

amino acid

antibody

acid sequence

set forth

Prior art date

2020-11-11

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• CIPO
• Discuss

• 239000000488 activin Substances 0.000 title claims abstract description 221
• 108010059616 Activins Proteins 0.000 title claims abstract description 185
• 102000005606 Activins Human genes 0.000 title claims abstract description 185
• 230000001588 bifunctional effect Effects 0.000 title claims abstract description 177
• 239000005557 antagonist Substances 0.000 title claims abstract description 156
• ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 title description 3
• 101150074062 Tnfsf11 gene Proteins 0.000 title 1
• 230000027455 binding Effects 0.000 claims abstract description 257
• 102000014128 RANK Ligand Human genes 0.000 claims abstract description 170
• 108010025832 RANK Ligand Proteins 0.000 claims abstract description 170
• 206010028980 Neoplasm Diseases 0.000 claims abstract description 53
• 210000000988 bone and bone Anatomy 0.000 claims abstract description 37
• 206010065687 Bone loss Diseases 0.000 claims abstract description 32
• 201000011510 cancer Diseases 0.000 claims abstract description 30
• 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 29
• 206010027476 Metastases Diseases 0.000 claims abstract description 24
• 230000009401 metastasis Effects 0.000 claims abstract description 23
• 230000019491 signal transduction Effects 0.000 claims abstract description 19
• 230000004913 activation Effects 0.000 claims abstract description 13
• 230000008506 pathogenesis Effects 0.000 claims abstract description 13
• 230000014759 maintenance of location Effects 0.000 claims abstract description 8
• 208000010392 Bone Fractures Diseases 0.000 claims abstract description 6
• 206010031243 Osteogenesis imperfecta Diseases 0.000 claims abstract description 6
• 208000001132 Osteoporosis Diseases 0.000 claims abstract description 6
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 277
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 202
• 239000000427 antigen Substances 0.000 claims description 169
• 102000036639 antigens Human genes 0.000 claims description 168
• 108091007433 antigens Proteins 0.000 claims description 168
• 102000004196 processed proteins & peptides Human genes 0.000 claims description 151
• 229920001184 polypeptide Polymers 0.000 claims description 148
• 239000003446 ligand Substances 0.000 claims description 121
• 239000012634 fragment Substances 0.000 claims description 72
• 238000000034 method Methods 0.000 claims description 66
• 239000000203 mixture Substances 0.000 claims description 59
• 108090000623 proteins and genes Proteins 0.000 claims description 59
• 102000004169 proteins and genes Human genes 0.000 claims description 48
• 102000040430 polynucleotide Human genes 0.000 claims description 44
• 108091033319 polynucleotide Proteins 0.000 claims description 44
• 239000002157 polynucleotide Substances 0.000 claims description 44
• 150000007523 nucleic acids Chemical class 0.000 claims description 42
• 102000039446 nucleic acids Human genes 0.000 claims description 40
• 108020004707 nucleic acids Proteins 0.000 claims description 40
• 230000014509 gene expression Effects 0.000 claims description 37
• 239000013598 vector Substances 0.000 claims description 37
• XXUPLYBCNPLTIW-UHFFFAOYSA-N octadec-7-ynoic acid Chemical compound CCCCCCCCCCC#CCCCCCC(O)=O XXUPLYBCNPLTIW-UHFFFAOYSA-N 0.000 claims description 35
• 102000008108 Osteoprotegerin Human genes 0.000 claims description 31
• 108010035042 Osteoprotegerin Proteins 0.000 claims description 31
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 31
• 230000011664 signaling Effects 0.000 claims description 29
• 102000005962 receptors Human genes 0.000 claims description 24
• 108020003175 receptors Proteins 0.000 claims description 24
• 201000010099 disease Diseases 0.000 claims description 16
• 208000035475 disorder Diseases 0.000 claims description 15
• 239000003937 drug carrier Substances 0.000 claims description 14
• 238000002823 phage display Methods 0.000 claims description 14
• 230000008685 targeting Effects 0.000 claims description 12
• 108010014612 Follistatin Proteins 0.000 claims description 11
• 102000016970 Follistatin Human genes 0.000 claims description 11
• 108060003951 Immunoglobulin Proteins 0.000 claims description 10
• 102000018358 immunoglobulin Human genes 0.000 claims description 10
• 239000003862 glucocorticoid Substances 0.000 claims description 9
• 238000004519 manufacturing process Methods 0.000 claims description 8
• 206010035226 Plasma cell myeloma Diseases 0.000 claims description 6
• 206010006895 Cachexia Diseases 0.000 claims description 5
• 208000034578 Multiple myelomas Diseases 0.000 claims description 5
• 206010028289 Muscle atrophy Diseases 0.000 claims description 5
• 230000003042 antagnostic effect Effects 0.000 claims description 5
• 230000001404 mediated effect Effects 0.000 claims description 5
• 201000000585 muscular atrophy Diseases 0.000 claims description 5
• 230000003389 potentiating effect Effects 0.000 claims description 5
• 238000002560 therapeutic procedure Methods 0.000 claims description 5
• 208000002966 Giant Cell Tumor of Bone Diseases 0.000 claims description 4
• 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
• 206010060862 Prostate cancer Diseases 0.000 claims description 4
• 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
• 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 4
• 201000011143 bone giant cell tumor Diseases 0.000 claims description 4
• 201000005202 lung cancer Diseases 0.000 claims description 4
• 208000020816 lung neoplasm Diseases 0.000 claims description 4
• 201000001441 melanoma Diseases 0.000 claims description 4
• 208000001076 sarcopenia Diseases 0.000 claims description 4
• 206010005003 Bladder cancer Diseases 0.000 claims description 3
• 208000003174 Brain Neoplasms Diseases 0.000 claims description 3
• 206010006187 Breast cancer Diseases 0.000 claims description 3
• 208000026310 Breast neoplasm Diseases 0.000 claims description 3
• 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 3
• 208000008839 Kidney Neoplasms Diseases 0.000 claims description 3
• 208000003076 Osteolysis Diseases 0.000 claims description 3
• 206010033128 Ovarian cancer Diseases 0.000 claims description 3
• 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
• 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
• 208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
• 238000009167 androgen deprivation therapy Methods 0.000 claims description 3
• 238000012258 culturing Methods 0.000 claims description 3
• 230000009977 dual effect Effects 0.000 claims description 3
• 208000029791 lytic metastatic bone lesion Diseases 0.000 claims description 3
• 201000005112 urinary bladder cancer Diseases 0.000 claims description 3
• 206010009944 Colon cancer Diseases 0.000 claims description 2
• 206010014733 Endometrial cancer Diseases 0.000 claims description 2
• 206010014759 Endometrial neoplasm Diseases 0.000 claims description 2
• 206010038389 Renal cancer Diseases 0.000 claims description 2
• 208000024313 Testicular Neoplasms Diseases 0.000 claims description 2
• 206010057644 Testis cancer Diseases 0.000 claims description 2
• 102000025683 activin binding proteins Human genes 0.000 claims description 2
• 108091014728 activin binding proteins Proteins 0.000 claims description 2
• 208000035269 cancer or benign tumor Diseases 0.000 claims description 2
• 206010017758 gastric cancer Diseases 0.000 claims description 2
• 201000010982 kidney cancer Diseases 0.000 claims description 2
• 208000014018 liver neoplasm Diseases 0.000 claims description 2
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
• 201000006938 muscular dystrophy Diseases 0.000 claims description 2
• 230000000010 osteolytic effect Effects 0.000 claims description 2
• 201000002528 pancreatic cancer Diseases 0.000 claims description 2
• 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
• 208000002320 spinal muscular atrophy Diseases 0.000 claims description 2
• 201000011549 stomach cancer Diseases 0.000 claims description 2
• 201000003120 testicular cancer Diseases 0.000 claims description 2
• 230000001131 transforming effect Effects 0.000 claims description 2
• 101100437153 Rattus norvegicus Acvr2b gene Proteins 0.000 claims 2
• 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 1
• 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims 1
• 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims 1
• 238000011262 co‐therapy Methods 0.000 claims 1
• 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 1
• 201000007270 liver cancer Diseases 0.000 claims 1
• 208000013077 thyroid gland carcinoma Diseases 0.000 claims 1
• 230000001225 therapeutic effect Effects 0.000 abstract description 19
• 208000020084 Bone disease Diseases 0.000 abstract description 9
• 208000018360 neuromuscular disease Diseases 0.000 abstract description 4
• 206010017076 Fracture Diseases 0.000 abstract description 3
• 208000029725 Metabolic bone disease Diseases 0.000 abstract description 3
• 206010049088 Osteopenia Diseases 0.000 abstract description 3
• 210000004027 cell Anatomy 0.000 description 83
• 238000011282 treatment Methods 0.000 description 62
• 235000001014 amino acid Nutrition 0.000 description 56
• 235000018102 proteins Nutrition 0.000 description 45
• 150000001413 amino acids Chemical class 0.000 description 44
• 229940024606 amino acid Drugs 0.000 description 43
• 108010023082 activin A Proteins 0.000 description 31
• 230000000694 effects Effects 0.000 description 29
• 230000015572 biosynthetic process Effects 0.000 description 26
• 239000003795 chemical substances by application Substances 0.000 description 25
• 210000002997 osteoclast Anatomy 0.000 description 24
• 238000006467 substitution reaction Methods 0.000 description 24
• 125000000539 amino acid group Chemical group 0.000 description 21
• -1 Ala Chemical compound 0.000 description 20
• 241000699670 Mus sp. Species 0.000 description 20
• 125000003729 nucleotide group Chemical group 0.000 description 20
• 108020004414 DNA Proteins 0.000 description 19
• 238000005755 formation reaction Methods 0.000 description 19
• 230000001965 increasing effect Effects 0.000 description 19
• 239000002773 nucleotide Substances 0.000 description 19
• 238000009396 hybridization Methods 0.000 description 18
• 238000004113 cell culture Methods 0.000 description 17
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 16
• 241000699666 Mus <mouse, genus> Species 0.000 description 16
• 230000000295 complement effect Effects 0.000 description 16
• 239000000523 sample Substances 0.000 description 15
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 14
• 238000003556 assay Methods 0.000 description 14
• 229960003957 dexamethasone Drugs 0.000 description 14
• UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 14
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 14
• 230000001105 regulatory effect Effects 0.000 description 14
• 108010021625 Immunoglobulin Fragments Proteins 0.000 description 13
• 102000008394 Immunoglobulin Fragments Human genes 0.000 description 13
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 13
• 102100039939 Growth/differentiation factor 8 Human genes 0.000 description 12
• 239000003814 drug Substances 0.000 description 12
• 239000013612 plasmid Substances 0.000 description 12
• 108010023079 activin B Proteins 0.000 description 11
• 239000013604 expression vector Substances 0.000 description 11
• 210000003205 muscle Anatomy 0.000 description 11
• 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 11
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 10
• 102100025751 Mothers against decapentaplegic homolog 2 Human genes 0.000 description 10
• 101710143123 Mothers against decapentaplegic homolog 2 Proteins 0.000 description 10
• 108010056852 Myostatin Proteins 0.000 description 10
• 150000001875 compounds Chemical class 0.000 description 10
• 241001465754 Metazoa Species 0.000 description 9
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
• CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 9
• 230000004071 biological effect Effects 0.000 description 9
• 210000004899 c-terminal region Anatomy 0.000 description 9
• 238000011284 combination treatment Methods 0.000 description 9
• 230000004048 modification Effects 0.000 description 9
• 238000012986 modification Methods 0.000 description 9
• 229920001223 polyethylene glycol Polymers 0.000 description 9
• 239000003981 vehicle Substances 0.000 description 9
• CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 8
• 206010016654 Fibrosis Diseases 0.000 description 8
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
• 108091028043 Nucleic acid sequence Proteins 0.000 description 8
• 238000004458 analytical method Methods 0.000 description 8
• 239000000872 buffer Substances 0.000 description 8
• 230000004761 fibrosis Effects 0.000 description 8
• 230000004927 fusion Effects 0.000 description 8
• 238000000746 purification Methods 0.000 description 8
• 241000894007 species Species 0.000 description 8
• 238000003786 synthesis reaction Methods 0.000 description 8
• 238000012360 testing method Methods 0.000 description 8
• 210000004881 tumor cell Anatomy 0.000 description 8
• 108010087819 Fc receptors Proteins 0.000 description 7
• 102000009109 Fc receptors Human genes 0.000 description 7
• 239000004471 Glycine Substances 0.000 description 7
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 7
• 239000004472 Lysine Substances 0.000 description 7
• 230000000890 antigenic effect Effects 0.000 description 7
• 230000024279 bone resorption Effects 0.000 description 7
• 210000003527 eukaryotic cell Anatomy 0.000 description 7
• 238000009472 formulation Methods 0.000 description 7
• 210000004408 hybridoma Anatomy 0.000 description 7
• 238000003384 imaging method Methods 0.000 description 7
• 238000010603 microCT Methods 0.000 description 7
• 230000011164 ossification Effects 0.000 description 7
• 238000002360 preparation method Methods 0.000 description 7
• 230000004044 response Effects 0.000 description 7
• 239000000243 solution Substances 0.000 description 7
• 239000000126 substance Chemical group 0.000 description 7
• UBWXUGDQUBIEIZ-UHFFFAOYSA-N (13-methyl-3-oxo-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-17-yl) 3-phenylpropanoate Chemical compound CC12CCC(C3CCC(=O)C=C3CC3)C3C1CCC2OC(=O)CCC1=CC=CC=C1 UBWXUGDQUBIEIZ-UHFFFAOYSA-N 0.000 description 6
• 102000053602 DNA Human genes 0.000 description 6
• 102100040898 Growth/differentiation factor 11 Human genes 0.000 description 6
• 101000937269 Homo sapiens Activin receptor type-2B Proteins 0.000 description 6
• 101000830603 Homo sapiens Tumor necrosis factor ligand superfamily member 11 Proteins 0.000 description 6
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 6
• AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 6
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 6
• 208000035896 Twin-reversed arterial perfusion sequence Diseases 0.000 description 6
• 230000007705 epithelial mesenchymal transition Effects 0.000 description 6
• 230000006870 function Effects 0.000 description 6
• 102000045412 human ACVR2B Human genes 0.000 description 6
• 102000053529 human TNFSF11 Human genes 0.000 description 6
• 238000009169 immunotherapy Methods 0.000 description 6
• 238000002347 injection Methods 0.000 description 6
• 239000007924 injection Substances 0.000 description 6
• 210000000056 organ Anatomy 0.000 description 6
• 239000000546 pharmaceutical excipient Substances 0.000 description 6
• 238000003127 radioimmunoassay Methods 0.000 description 6
• 230000007781 signaling event Effects 0.000 description 6
• 239000000725 suspension Substances 0.000 description 6
• 229940124597 therapeutic agent Drugs 0.000 description 6
• 210000000689 upper leg Anatomy 0.000 description 6
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 5
• 102000018918 Activin Receptors Human genes 0.000 description 5
• 108010052946 Activin Receptors Proteins 0.000 description 5
• 208000006386 Bone Resorption Diseases 0.000 description 5
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 5
• 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 5
• 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 5
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 5
• 241000124008 Mammalia Species 0.000 description 5
• 239000004793 Polystyrene Substances 0.000 description 5
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 5
• 239000004473 Threonine Substances 0.000 description 5
• 108020000411 Toll-like receptor Proteins 0.000 description 5
• 102000002689 Toll-like receptor Human genes 0.000 description 5
• KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 5
• 238000007792 addition Methods 0.000 description 5
• 238000012575 bio-layer interferometry Methods 0.000 description 5
• 230000033228 biological regulation Effects 0.000 description 5
• 238000002648 combination therapy Methods 0.000 description 5
• 239000002299 complementary DNA Substances 0.000 description 5
• 230000000875 corresponding effect Effects 0.000 description 5
• 239000002552 dosage form Substances 0.000 description 5
• 239000012636 effector Substances 0.000 description 5
• 238000005516 engineering process Methods 0.000 description 5
• 238000002474 experimental method Methods 0.000 description 5
• 102000037865 fusion proteins Human genes 0.000 description 5
• 108020001507 fusion proteins Proteins 0.000 description 5
• 238000001727 in vivo Methods 0.000 description 5
• 230000002401 inhibitory effect Effects 0.000 description 5
• 230000003993 interaction Effects 0.000 description 5
• 239000003550 marker Substances 0.000 description 5
• 108020004999 messenger RNA Proteins 0.000 description 5
• 239000003921 oil Substances 0.000 description 5
• 235000019198 oils Nutrition 0.000 description 5
• 210000001236 prokaryotic cell Anatomy 0.000 description 5
• 230000002829 reductive effect Effects 0.000 description 5
• 150000003839 salts Chemical class 0.000 description 5
• 239000000600 sorbitol Substances 0.000 description 5
• 208000024891 symptom Diseases 0.000 description 5
• 230000009261 transgenic effect Effects 0.000 description 5
• 239000004475 Arginine Substances 0.000 description 4
• DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 4
• 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 4
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
• 102000003886 Glycoproteins Human genes 0.000 description 4
• 108090000288 Glycoproteins Proteins 0.000 description 4
• 101710194452 Growth/differentiation factor 11 Proteins 0.000 description 4
• 101000931668 Homo sapiens Follistatin Proteins 0.000 description 4
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 4
• DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 4
• AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 4
• QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 4
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
• 229930195725 Mannitol Natural products 0.000 description 4
• 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 4
• 102000001708 Protein Isoforms Human genes 0.000 description 4
• 108010029485 Protein Isoforms Proteins 0.000 description 4
• 241000283984 Rodentia Species 0.000 description 4
• 108010003723 Single-Domain Antibodies Proteins 0.000 description 4
• 229930006000 Sucrose Natural products 0.000 description 4
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
• 210000001744 T-lymphocyte Anatomy 0.000 description 4
• QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 4
• 230000009471 action Effects 0.000 description 4
• 235000004279 alanine Nutrition 0.000 description 4
• 238000011319 anticancer therapy Methods 0.000 description 4
• 239000007864 aqueous solution Substances 0.000 description 4
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 4
• 235000009582 asparagine Nutrition 0.000 description 4
• 229960001230 asparagine Drugs 0.000 description 4
• 230000008901 benefit Effects 0.000 description 4
• 230000000903 blocking effect Effects 0.000 description 4
• 230000010072 bone remodeling Effects 0.000 description 4
• 238000004422 calculation algorithm Methods 0.000 description 4
• 229910002092 carbon dioxide Inorganic materials 0.000 description 4
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
• 230000024245 cell differentiation Effects 0.000 description 4
• 125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 description 4
• 239000000032 diagnostic agent Substances 0.000 description 4
• 229940039227 diagnostic agent Drugs 0.000 description 4
• 238000010494 dissociation reaction Methods 0.000 description 4
• 230000005593 dissociations Effects 0.000 description 4
• 239000000839 emulsion Substances 0.000 description 4
• 239000003623 enhancer Substances 0.000 description 4
• 239000000499 gel Substances 0.000 description 4
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 4
• 230000011132 hemopoiesis Effects 0.000 description 4
• 102000050536 human FST Human genes 0.000 description 4
• 230000003053 immunization Effects 0.000 description 4
• 238000002513 implantation Methods 0.000 description 4
• 230000005764 inhibitory process Effects 0.000 description 4
• 208000032839 leukemia Diseases 0.000 description 4
• 239000002502 liposome Substances 0.000 description 4
• 239000000594 mannitol Substances 0.000 description 4
• 235000010355 mannitol Nutrition 0.000 description 4
• 230000035772 mutation Effects 0.000 description 4
• 229920000642 polymer Polymers 0.000 description 4
• 239000003755 preservative agent Substances 0.000 description 4
• 230000010076 replication Effects 0.000 description 4
• YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
• 238000012216 screening Methods 0.000 description 4
• 230000022379 skeletal muscle tissue development Effects 0.000 description 4
• 239000005720 sucrose Substances 0.000 description 4
• 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 4
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 4
• 239000000080 wetting agent Substances 0.000 description 4
• MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
• 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
• 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
• 101000798130 Homo sapiens Tumor necrosis factor receptor superfamily member 11B Proteins 0.000 description 3
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
• 206010022489 Insulin Resistance Diseases 0.000 description 3
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
• LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 3
• KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 3
• 108060001084 Luciferase Proteins 0.000 description 3
• 239000005089 Luciferase Substances 0.000 description 3
• 206010025323 Lymphomas Diseases 0.000 description 3
• 241001529936 Murinae Species 0.000 description 3
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
• 208000002193 Pain Diseases 0.000 description 3
• 239000004698 Polyethylene Substances 0.000 description 3
• 241000700159 Rattus Species 0.000 description 3
• 108020004511 Recombinant DNA Proteins 0.000 description 3
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
• 206010039491 Sarcoma Diseases 0.000 description 3
• 229920002472 Starch Polymers 0.000 description 3
• 241000700605 Viruses Species 0.000 description 3
• 239000002253 acid Substances 0.000 description 3
• 230000003213 activating effect Effects 0.000 description 3
• 239000008186 active pharmaceutical agent Substances 0.000 description 3
• 208000007502 anemia Diseases 0.000 description 3
• 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 3
• 210000000628 antibody-producing cell Anatomy 0.000 description 3
• 230000001580 bacterial effect Effects 0.000 description 3
• 239000002585 base Substances 0.000 description 3
• 239000002775 capsule Substances 0.000 description 3
• 230000004663 cell proliferation Effects 0.000 description 3
• 210000004978 chinese hamster ovary cell Anatomy 0.000 description 3
• 208000020832 chronic kidney disease Diseases 0.000 description 3
• 235000018417 cysteine Nutrition 0.000 description 3
• 230000003247 decreasing effect Effects 0.000 description 3
• 239000003995 emulsifying agent Substances 0.000 description 3
• 230000007613 environmental effect Effects 0.000 description 3
• 210000002744 extracellular matrix Anatomy 0.000 description 3
• 239000000945 filler Substances 0.000 description 3
• 238000000684 flow cytometry Methods 0.000 description 3
• 235000011187 glycerol Nutrition 0.000 description 3
• 230000036541 health Effects 0.000 description 3
• 238000004128 high performance liquid chromatography Methods 0.000 description 3
• 102000052781 human TNFRSF11B Human genes 0.000 description 3
• 230000036737 immune function Effects 0.000 description 3
• 230000002163 immunogen Effects 0.000 description 3
• 230000006698 induction Effects 0.000 description 3
• 230000000977 initiatory effect Effects 0.000 description 3
• 229960000310 isoleucine Drugs 0.000 description 3
• AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 3
• 208000019423 liver disease Diseases 0.000 description 3
• 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 3
• 239000000463 material Substances 0.000 description 3
• 239000002609 medium Substances 0.000 description 3
• 239000012528 membrane Substances 0.000 description 3
• 229930182817 methionine Natural products 0.000 description 3
• 210000005088 multinucleated cell Anatomy 0.000 description 3
• 230000003472 neutralizing effect Effects 0.000 description 3
• 210000000963 osteoblast Anatomy 0.000 description 3
• 230000000144 pharmacologic effect Effects 0.000 description 3
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 3
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
• 229960004063 propylene glycol Drugs 0.000 description 3
• 230000001850 reproductive effect Effects 0.000 description 3
• 230000002441 reversible effect Effects 0.000 description 3
• 238000012552 review Methods 0.000 description 3
• RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 3
• 210000003491 skin Anatomy 0.000 description 3
• 235000015424 sodium Nutrition 0.000 description 3
• 239000002904 solvent Substances 0.000 description 3
• 238000010186 staining Methods 0.000 description 3
• 235000019698 starch Nutrition 0.000 description 3
• 238000001356 surgical procedure Methods 0.000 description 3
• 239000003826 tablet Substances 0.000 description 3
• 210000001519 tissue Anatomy 0.000 description 3
• 208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
• 241000701447 unidentified baculovirus Species 0.000 description 3
• 239000004474 valine Substances 0.000 description 3
• 230000003442 weekly effect Effects 0.000 description 3
• PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
• JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
• IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
• VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
• WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
• 108010016587 288-amino acid isoform follistatin Proteins 0.000 description 2
• QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical class N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
• 241000894006 Bacteria Species 0.000 description 2
• 241000701822 Bovine papillomavirus Species 0.000 description 2
• 108010021064 CTLA-4 Antigen Proteins 0.000 description 2
• 229940045513 CTLA4 antagonist Drugs 0.000 description 2
• VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
• 208000024172 Cardiovascular disease Diseases 0.000 description 2
• 108020004635 Complementary DNA Proteins 0.000 description 2
• 241000699800 Cricetinae Species 0.000 description 2
• 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 2
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
• 238000002965 ELISA Methods 0.000 description 2
• 102000004190 Enzymes Human genes 0.000 description 2
• 108090000790 Enzymes Proteins 0.000 description 2
• 241000588724 Escherichia coli Species 0.000 description 2
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
• 241000206602 Eukaryota Species 0.000 description 2
• WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
• 108010010803 Gelatin Proteins 0.000 description 2
• 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
• 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
• 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 2
• 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 description 2
• 241000238631 Hexapoda Species 0.000 description 2
• 208000017604 Hodgkin disease Diseases 0.000 description 2
• 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
• 241000282412 Homo Species 0.000 description 2
• 101000970954 Homo sapiens Activin receptor type-2A Proteins 0.000 description 2
• 101000893545 Homo sapiens Growth/differentiation factor 11 Proteins 0.000 description 2
• 101000886562 Homo sapiens Growth/differentiation factor 8 Proteins 0.000 description 2
• 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 description 2
• 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 description 2
• 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 description 2
• 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 description 2
• 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 description 2
• 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 description 2
• MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
• 102000037982 Immune checkpoint proteins Human genes 0.000 description 2
• 108091008036 Immune checkpoint proteins Proteins 0.000 description 2
• 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 2
• 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 2
• 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 2
• 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 2
• 108010065805 Interleukin-12 Proteins 0.000 description 2
• 108090000172 Interleukin-15 Proteins 0.000 description 2
• 102000017578 LAG3 Human genes 0.000 description 2
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
• 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 description 2
• SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
• 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
• 108020004711 Nucleic Acid Probes Proteins 0.000 description 2
• 108091034117 Oligonucleotide Proteins 0.000 description 2
• 108091005804 Peptidases Proteins 0.000 description 2
• 102000035195 Peptidases Human genes 0.000 description 2
• 108091093037 Peptide nucleic acid Proteins 0.000 description 2
• 239000002202 Polyethylene glycol Substances 0.000 description 2
• WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
• ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
• 239000004365 Protease Substances 0.000 description 2
• 108010076504 Protein Sorting Signals Proteins 0.000 description 2
• 108010071390 Serum Albumin Proteins 0.000 description 2
• 102000007562 Serum Albumin Human genes 0.000 description 2
• 208000000453 Skin Neoplasms Diseases 0.000 description 2
• 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 description 2
• 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 description 2
• 102100040247 Tumor necrosis factor Human genes 0.000 description 2
• 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 description 2
• 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 description 2
• 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 description 2
• 208000010399 Wasting Syndrome Diseases 0.000 description 2
• XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
• RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
• 239000002671 adjuvant Substances 0.000 description 2
• 238000001042 affinity chromatography Methods 0.000 description 2
• 239000000556 agonist Substances 0.000 description 2
• 230000001270 agonistic effect Effects 0.000 description 2
• 235000010443 alginic acid Nutrition 0.000 description 2
• 229920000615 alginic acid Polymers 0.000 description 2
• 238000010171 animal model Methods 0.000 description 2
• 230000000259 anti-tumor effect Effects 0.000 description 2
• 239000000611 antibody drug conjugate Substances 0.000 description 2
• 230000005888 antibody-dependent cellular phagocytosis Effects 0.000 description 2
• 229940049595 antibody-drug conjugate Drugs 0.000 description 2
• 210000001106 artificial yeast chromosome Anatomy 0.000 description 2
• 229940009098 aspartate Drugs 0.000 description 2
• 230000002238 attenuated effect Effects 0.000 description 2
• 239000011324 bead Substances 0.000 description 2
• 235000012216 bentonite Nutrition 0.000 description 2
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
• SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
• 230000008827 biological function Effects 0.000 description 2
• 125000004057 biotinyl group Chemical group [H]N1C(=O)N([H])[C@]2([H])[C@@]([H])(SC([H])([H])[C@]12[H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 description 2
• 229960003008 blinatumomab Drugs 0.000 description 2
• 230000037396 body weight Effects 0.000 description 2
• 210000004556 brain Anatomy 0.000 description 2
• 239000007975 buffered saline Substances 0.000 description 2
• RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
• 150000001720 carbohydrates Chemical group 0.000 description 2
• 239000001768 carboxy methyl cellulose Substances 0.000 description 2
• 239000000969 carrier Substances 0.000 description 2
• 238000000423 cell based assay Methods 0.000 description 2
• 230000001413 cellular effect Effects 0.000 description 2
• 230000008859 change Effects 0.000 description 2
• 208000006990 cholangiocarcinoma Diseases 0.000 description 2
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
• 238000004587 chromatography analysis Methods 0.000 description 2
• 238000011278 co-treatment Methods 0.000 description 2
• 238000001246 colloidal dispersion Methods 0.000 description 2
• 239000003086 colorant Substances 0.000 description 2
• 238000004040 coloring Methods 0.000 description 2
• 230000004540 complement-dependent cytotoxicity Effects 0.000 description 2
• 238000002591 computed tomography Methods 0.000 description 2
• 230000021615 conjugation Effects 0.000 description 2
• 230000002596 correlated effect Effects 0.000 description 2
• 239000006071 cream Substances 0.000 description 2
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
• 230000007423 decrease Effects 0.000 description 2
• 230000002950 deficient Effects 0.000 description 2
• 238000012217 deletion Methods 0.000 description 2
• 230000037430 deletion Effects 0.000 description 2
• 229940029030 dendritic cell vaccine Drugs 0.000 description 2
• 230000000779 depleting effect Effects 0.000 description 2
• 238000001514 detection method Methods 0.000 description 2
• 230000029087 digestion Effects 0.000 description 2
• 239000003085 diluting agent Substances 0.000 description 2
• 239000003651 drinking water Substances 0.000 description 2
• 235000020188 drinking water Nutrition 0.000 description 2
• 230000002255 enzymatic effect Effects 0.000 description 2
• 229940088598 enzyme Drugs 0.000 description 2
• 239000013613 expression plasmid Substances 0.000 description 2
• 210000002950 fibroblast Anatomy 0.000 description 2
• 239000000796 flavoring agent Substances 0.000 description 2
• 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
• IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 description 2
• 238000005194 fractionation Methods 0.000 description 2
• 210000001035 gastrointestinal tract Anatomy 0.000 description 2
• 239000008273 gelatin Substances 0.000 description 2
• 229920000159 gelatin Polymers 0.000 description 2
• 235000019322 gelatine Nutrition 0.000 description 2
• 235000011852 gelatine desserts Nutrition 0.000 description 2
• 210000004602 germ cell Anatomy 0.000 description 2
• 239000008103 glucose Substances 0.000 description 2
• 229930195712 glutamate Natural products 0.000 description 2
• 230000013595 glycosylation Effects 0.000 description 2
• 238000006206 glycosylation reaction Methods 0.000 description 2
• 239000001963 growth medium Substances 0.000 description 2
• 208000014829 head and neck neoplasm Diseases 0.000 description 2
• 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
• 210000005260 human cell Anatomy 0.000 description 2
• 229960002751 imiquimod Drugs 0.000 description 2
• DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 2
• 230000001900 immune effect Effects 0.000 description 2
• 230000028993 immune response Effects 0.000 description 2
• 210000000987 immune system Anatomy 0.000 description 2
• 239000000367 immunologic factor Substances 0.000 description 2
• 230000003308 immunostimulating effect Effects 0.000 description 2
• 238000010348 incorporation Methods 0.000 description 2
• 238000011534 incubation Methods 0.000 description 2
• 239000003701 inert diluent Substances 0.000 description 2
• 238000001802 infusion Methods 0.000 description 2
• 239000003112 inhibitor Substances 0.000 description 2
• 108010074108 interleukin-21 Proteins 0.000 description 2
• 238000007912 intraperitoneal administration Methods 0.000 description 2
• 239000008101 lactose Substances 0.000 description 2
• 230000000670 limiting effect Effects 0.000 description 2
• 150000002632 lipids Chemical class 0.000 description 2
• 239000008297 liquid dosage form Substances 0.000 description 2
• 210000004185 liver Anatomy 0.000 description 2
• 229920002521 macromolecule Polymers 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• 229910052751 metal Inorganic materials 0.000 description 2
• 239000002184 metal Substances 0.000 description 2
• 206010061289 metastatic neoplasm Diseases 0.000 description 2
• OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Natural products OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 2
• LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
• 239000000693 micelle Substances 0.000 description 2
• 230000003278 mimic effect Effects 0.000 description 2
• 238000010369 molecular cloning Methods 0.000 description 2
• 238000007491 morphometric analysis Methods 0.000 description 2
• 230000004220 muscle function Effects 0.000 description 2
• 239000002853 nucleic acid probe Substances 0.000 description 2
• 239000002674 ointment Substances 0.000 description 2
• 230000010258 osteoblastogenesis Effects 0.000 description 2
• 201000008968 osteosarcoma Diseases 0.000 description 2
• 230000002018 overexpression Effects 0.000 description 2
• FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
• 238000007911 parenteral administration Methods 0.000 description 2
• 239000006072 paste Substances 0.000 description 2
• 230000035515 penetration Effects 0.000 description 2
• 229940023041 peptide vaccine Drugs 0.000 description 2
• 239000002953 phosphate buffered saline Substances 0.000 description 2
• WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 2
• 239000006187 pill Substances 0.000 description 2
• 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
• 239000000843 powder Substances 0.000 description 2
• 230000008569 process Effects 0.000 description 2
• 230000035755 proliferation Effects 0.000 description 2
• 230000000644 propagated effect Effects 0.000 description 2
• 230000000069 prophylactic effect Effects 0.000 description 2
• 238000011321 prophylaxis Methods 0.000 description 2
• AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
• QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
• RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
• 230000002285 radioactive effect Effects 0.000 description 2
• 238000001959 radiotherapy Methods 0.000 description 2
• 230000009467 reduction Effects 0.000 description 2
• 208000016691 refractory malignant neoplasm Diseases 0.000 description 2
• 238000007634 remodeling Methods 0.000 description 2
• 230000037195 reproductive physiology Effects 0.000 description 2
• 210000002345 respiratory system Anatomy 0.000 description 2
• 229960004889 salicylic acid Drugs 0.000 description 2
• 235000012239 silicon dioxide Nutrition 0.000 description 2
• 229960000714 sipuleucel-t Drugs 0.000 description 2
• 239000011734 sodium Substances 0.000 description 2
• 229910052708 sodium Inorganic materials 0.000 description 2
• 239000011780 sodium chloride Substances 0.000 description 2
• FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Inorganic materials [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
• GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
• 239000007909 solid dosage form Substances 0.000 description 2
• 125000006850 spacer group Chemical group 0.000 description 2
• 239000003381 stabilizer Substances 0.000 description 2
• 239000008107 starch Substances 0.000 description 2
• 238000011476 stem cell transplantation Methods 0.000 description 2
• 230000004936 stimulating effect Effects 0.000 description 2
• 239000004094 surface-active agent Substances 0.000 description 2
• 239000000375 suspending agent Substances 0.000 description 2
• 239000000454 talc Substances 0.000 description 2
• 235000012222 talc Nutrition 0.000 description 2
• 229910052623 talc Inorganic materials 0.000 description 2
• 238000002626 targeted therapy Methods 0.000 description 2
• 231100001274 therapeutic index Toxicity 0.000 description 2
• 229940021747 therapeutic vaccine Drugs 0.000 description 2
• 230000000699 topical effect Effects 0.000 description 2
• 231100000331 toxic Toxicity 0.000 description 2
• 230000002588 toxic effect Effects 0.000 description 2
• 230000001988 toxicity Effects 0.000 description 2
• 231100000419 toxicity Toxicity 0.000 description 2
• 239000003053 toxin Substances 0.000 description 2
• 231100000765 toxin Toxicity 0.000 description 2
• 108700012359 toxins Proteins 0.000 description 2
• 238000013518 transcription Methods 0.000 description 2
• 230000035897 transcription Effects 0.000 description 2
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
• 241000701161 unidentified adenovirus Species 0.000 description 2
• 210000001635 urinary tract Anatomy 0.000 description 2
• 230000003612 virological effect Effects 0.000 description 2
• 239000001993 wax Substances 0.000 description 2
• JARGNLJYKBUKSJ-KGZKBUQUSA-N (2r)-2-amino-5-[[(2r)-1-(carboxymethylamino)-3-hydroxy-1-oxopropan-2-yl]amino]-5-oxopentanoic acid;hydrobromide Chemical compound Br.OC(=O)[C@H](N)CCC(=O)N[C@H](CO)C(=O)NCC(O)=O JARGNLJYKBUKSJ-KGZKBUQUSA-N 0.000 description 1
• KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 1
• NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 description 1
• TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
• 229940058015 1,3-butylene glycol Drugs 0.000 description 1
• AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 1
• NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
• GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
• JNODDICFTDYODH-UHFFFAOYSA-N 2-hydroxytetrahydrofuran Chemical compound OC1CCCO1 JNODDICFTDYODH-UHFFFAOYSA-N 0.000 description 1
• OSJPPGNTCRNQQC-UWTATZPHSA-N 3-phospho-D-glyceric acid Chemical compound OC(=O)[C@H](O)COP(O)(O)=O OSJPPGNTCRNQQC-UWTATZPHSA-N 0.000 description 1
• STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
• 208000030507 AIDS Diseases 0.000 description 1
• 208000002008 AIDS-Related Lymphoma Diseases 0.000 description 1
• 102000013563 Acid Phosphatase Human genes 0.000 description 1
• 108010051457 Acid Phosphatase Proteins 0.000 description 1
• 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
• 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
• 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
• 229920001817 Agar Polymers 0.000 description 1
• WQVFQXXBNHHPLX-ZKWXMUAHSA-N Ala-Ala-His Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1cnc[nH]1)C(O)=O WQVFQXXBNHHPLX-ZKWXMUAHSA-N 0.000 description 1
• NBTGEURICRTMGL-WHFBIAKZSA-N Ala-Gly-Ser Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O NBTGEURICRTMGL-WHFBIAKZSA-N 0.000 description 1
• IPWKGIFRRBGCJO-IMJSIDKUSA-N Ala-Ser Chemical compound C[C@H]([NH3+])C(=O)N[C@@H](CO)C([O-])=O IPWKGIFRRBGCJO-IMJSIDKUSA-N 0.000 description 1
• 108010088751 Albumins Proteins 0.000 description 1
• 102000009027 Albumins Human genes 0.000 description 1
• 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
• 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
• 239000005995 Aluminium silicate Substances 0.000 description 1
• 208000007860 Anus Neoplasms Diseases 0.000 description 1
• 235000003276 Apios tuberosa Nutrition 0.000 description 1
• 244000105624 Arachis hypogaea Species 0.000 description 1
• 235000010777 Arachis hypogaea Nutrition 0.000 description 1
• 235000010744 Arachis villosulicarpa Nutrition 0.000 description 1
• BHSYMWWMVRPCPA-CYDGBPFRSA-N Arg-Arg-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CCCN=C(N)N BHSYMWWMVRPCPA-CYDGBPFRSA-N 0.000 description 1
• LJUOLNXOWSWGKF-ACZMJKKPSA-N Asn-Asn-Glu Chemical compound C(CC(=O)O)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)N)N LJUOLNXOWSWGKF-ACZMJKKPSA-N 0.000 description 1
• KHCNTVRVAYCPQE-CIUDSAMLSA-N Asn-Lys-Asn Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O KHCNTVRVAYCPQE-CIUDSAMLSA-N 0.000 description 1
• AEZCCDMZZJOGII-DCAQKATOSA-N Asn-Met-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(O)=O AEZCCDMZZJOGII-DCAQKATOSA-N 0.000 description 1
• FANQWNCPNFEPGZ-WHFBIAKZSA-N Asp-Asp-Gly Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O FANQWNCPNFEPGZ-WHFBIAKZSA-N 0.000 description 1
• RATOMFTUDRYMKX-ACZMJKKPSA-N Asp-Glu-Cys Chemical compound C(CC(=O)O)[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC(=O)O)N RATOMFTUDRYMKX-ACZMJKKPSA-N 0.000 description 1
• 241000416162 Astragalus gummifer Species 0.000 description 1
• 206010003571 Astrocytoma Diseases 0.000 description 1
• 206010060971 Astrocytoma malignant Diseases 0.000 description 1
• 241000271566 Aves Species 0.000 description 1
• 108090001008 Avidin Proteins 0.000 description 1
• 108091008875 B cell receptors Proteins 0.000 description 1
• 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
• 230000003844 B-cell-activation Effects 0.000 description 1
• 108010074708 B7-H1 Antigen Proteins 0.000 description 1
• 241000304886 Bacilli Species 0.000 description 1
• 239000005711 Benzoic acid Substances 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
• 206010005949 Bone cancer Diseases 0.000 description 1
• 208000018084 Bone neoplasm Diseases 0.000 description 1
• BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• 208000023706 Bruton agammaglobulinaemia Diseases 0.000 description 1
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
• 241000282465 Canis Species 0.000 description 1
• 101710132601 Capsid protein Proteins 0.000 description 1
• 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
• 241000700199 Cavia porcellus Species 0.000 description 1
• 102000000844 Cell Surface Receptors Human genes 0.000 description 1
• 108010001857 Cell Surface Receptors Proteins 0.000 description 1
• 241000282693 Cercopithecidae Species 0.000 description 1
• 206010008342 Cervix carcinoma Diseases 0.000 description 1
• GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
• 208000005243 Chondrosarcoma Diseases 0.000 description 1
• 101710094648 Coat protein Proteins 0.000 description 1
• 108091026890 Coding region Proteins 0.000 description 1
• 108091033380 Coding strand Proteins 0.000 description 1
• 102100033601 Collagen alpha-1(I) chain Human genes 0.000 description 1
• 102100036213 Collagen alpha-2(I) chain Human genes 0.000 description 1
• 102100031502 Collagen alpha-2(V) chain Human genes 0.000 description 1
• 102100024338 Collagen alpha-3(VI) chain Human genes 0.000 description 1
• 206010010356 Congenital anomaly Diseases 0.000 description 1
• 229920000858 Cyclodextrin Polymers 0.000 description 1
• NAPULYCVEVVFRB-HEIBUPTGSA-N Cys-Thr-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](N)CS NAPULYCVEVVFRB-HEIBUPTGSA-N 0.000 description 1
• 102000004127 Cytokines Human genes 0.000 description 1
• 108090000695 Cytokines Proteins 0.000 description 1
• 241000701022 Cytomegalovirus Species 0.000 description 1
• WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
• 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
• 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
• 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
• 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
• 108010092160 Dactinomycin Proteins 0.000 description 1
• 241000702421 Dependoparvovirus Species 0.000 description 1
• 229920002307 Dextran Polymers 0.000 description 1
• 239000004375 Dextrin Substances 0.000 description 1
• 229920001353 Dextrin Polymers 0.000 description 1
• 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
• 206010061818 Disease progression Diseases 0.000 description 1
• 206010059866 Drug resistance Diseases 0.000 description 1
• 241000196324 Embryophyta Species 0.000 description 1
• MBYXEBXZARTUSS-QLWBXOBMSA-N Emetamine Natural products O(C)c1c(OC)cc2c(c(C[C@@H]3[C@H](CC)CN4[C@H](c5c(cc(OC)c(OC)c5)CC4)C3)ncc2)c1 MBYXEBXZARTUSS-QLWBXOBMSA-N 0.000 description 1
• 206010014967 Ependymoma Diseases 0.000 description 1
• 241000283073 Equus caballus Species 0.000 description 1
• 241000701959 Escherichia virus Lambda Species 0.000 description 1
• 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
• 208000006168 Ewing Sarcoma Diseases 0.000 description 1
• 239000001116 FEMA 4028 Substances 0.000 description 1
• 241000282324 Felis Species 0.000 description 1
• 239000004606 Fillers/Extenders Substances 0.000 description 1
• 241000233866 Fungi Species 0.000 description 1
• 229910052688 Gadolinium Inorganic materials 0.000 description 1
• 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
• 241000206672 Gelidium Species 0.000 description 1
• 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
• 208000032612 Glial tumor Diseases 0.000 description 1
• 206010018338 Glioma Diseases 0.000 description 1
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
• JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
• ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
• 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
• 108010026389 Gramicidin Proteins 0.000 description 1
• 206010019280 Heart failures Diseases 0.000 description 1
• HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
• 208000028782 Hereditary disease Diseases 0.000 description 1
• 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 1
• 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
• 206010020100 Hip fracture Diseases 0.000 description 1
• 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
• 101000875067 Homo sapiens Collagen alpha-2(I) chain Proteins 0.000 description 1
• 101000941594 Homo sapiens Collagen alpha-2(V) chain Proteins 0.000 description 1
• 101000909506 Homo sapiens Collagen alpha-3(VI) chain Proteins 0.000 description 1
• 101000935587 Homo sapiens Flavin reductase (NADPH) Proteins 0.000 description 1
• 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 1
• 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
• 101000709472 Homo sapiens Sialic acid-binding Ig-like lectin 15 Proteins 0.000 description 1
• 101000863884 Homo sapiens Sialic acid-binding Ig-like lectin 8 Proteins 0.000 description 1
• 101000863883 Homo sapiens Sialic acid-binding Ig-like lectin 9 Proteins 0.000 description 1
• 101000863873 Homo sapiens Tyrosine-protein phosphatase non-receptor type substrate 1 Proteins 0.000 description 1
• 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
• 102000003839 Human Proteins Human genes 0.000 description 1
• 108090000144 Human Proteins Proteins 0.000 description 1
• 102000008100 Human Serum Albumin Human genes 0.000 description 1
• 108091006905 Human Serum Albumin Proteins 0.000 description 1
• 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
• 208000007924 IgA Deficiency Diseases 0.000 description 1
• IOVUXUSIGXCREV-DKIMLUQUSA-N Ile-Leu-Phe Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 IOVUXUSIGXCREV-DKIMLUQUSA-N 0.000 description 1
• 206010061598 Immunodeficiency Diseases 0.000 description 1
• 108010002352 Interleukin-1 Proteins 0.000 description 1
• 108050003558 Interleukin-17 Proteins 0.000 description 1
• 108010002350 Interleukin-2 Proteins 0.000 description 1
• 108090000978 Interleukin-4 Proteins 0.000 description 1
• 108010002586 Interleukin-7 Proteins 0.000 description 1
• 208000037396 Intraductal Noninfiltrating Carcinoma Diseases 0.000 description 1
• 206010073094 Intraductal proliferative breast lesion Diseases 0.000 description 1
• 206010061252 Intraocular melanoma Diseases 0.000 description 1
• LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
• 208000007766 Kaposi sarcoma Diseases 0.000 description 1
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
• LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
• 240000007472 Leucaena leucocephala Species 0.000 description 1
• 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
• NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
• 239000004367 Lipase Substances 0.000 description 1
• 108090001060 Lipase Proteins 0.000 description 1
• 102000004882 Lipase Human genes 0.000 description 1
• 206010073099 Lobular breast carcinoma in situ Diseases 0.000 description 1
• 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 description 1
• 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
• 206010025312 Lymphoma AIDS related Diseases 0.000 description 1
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
• 101710125418 Major capsid protein Proteins 0.000 description 1
• 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 description 1
• 240000003183 Manihot esculenta Species 0.000 description 1
• 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
• 208000000172 Medulloblastoma Diseases 0.000 description 1
• 229930192392 Mitomycin Natural products 0.000 description 1
• 206010027761 Mixed hepatocellular cholangiocarcinoma Diseases 0.000 description 1
• 102000007474 Multiprotein Complexes Human genes 0.000 description 1
• 108010085220 Multiprotein Complexes Proteins 0.000 description 1
• 101100060131 Mus musculus Cdk5rap2 gene Proteins 0.000 description 1
• 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
• NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
• FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
• BKAYIFDRRZZKNF-VIFPVBQESA-N N-acetylcarnosine Chemical compound CC(=O)NCCC(=O)N[C@H](C(O)=O)CC1=CN=CN1 BKAYIFDRRZZKNF-VIFPVBQESA-N 0.000 description 1
• KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 description 1
• 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
• 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
• 208000009277 Neuroectodermal Tumors Diseases 0.000 description 1
• 244000061176 Nicotiana tabacum Species 0.000 description 1
• 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
• 238000000636 Northern blotting Methods 0.000 description 1
• 101710163270 Nuclease Proteins 0.000 description 1
• 101710141454 Nucleoprotein Proteins 0.000 description 1
• 240000007817 Olea europaea Species 0.000 description 1
• 241000283973 Oryctolagus cuniculus Species 0.000 description 1
• 229910019142 PO4 Inorganic materials 0.000 description 1
• 229930012538 Paclitaxel Natural products 0.000 description 1
• 108090000526 Papain Proteins 0.000 description 1
• 208000002471 Penile Neoplasms Diseases 0.000 description 1
• 102000057297 Pepsin A Human genes 0.000 description 1
• 108090000284 Pepsin A Proteins 0.000 description 1
• 108010081690 Pertussis Toxin Proteins 0.000 description 1
• DMEYUTSDVRCWRS-ULQDDVLXSA-N Phe-Lys-Arg Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC1=CC=CC=C1 DMEYUTSDVRCWRS-ULQDDVLXSA-N 0.000 description 1
• KIQUCMUULDXTAZ-HJOGWXRNSA-N Phe-Tyr-Tyr Chemical compound N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(O)=O KIQUCMUULDXTAZ-HJOGWXRNSA-N 0.000 description 1
• 108091000080 Phosphotransferase Proteins 0.000 description 1
• 208000007641 Pinealoma Diseases 0.000 description 1
• 201000008199 Pleuropulmonary blastoma Diseases 0.000 description 1
• 229920001213 Polysorbate 20 Polymers 0.000 description 1
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
• 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
• 241000288906 Primates Species 0.000 description 1
• 101710083689 Probable capsid protein Proteins 0.000 description 1
• 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 1
• 239000012980 RPMI-1640 medium Substances 0.000 description 1
• 208000015634 Rectal Neoplasms Diseases 0.000 description 1
• 206010070308 Refractory cancer Diseases 0.000 description 1
• 201000000582 Retinoblastoma Diseases 0.000 description 1
• 108091028664 Ribonucleotide Proteins 0.000 description 1
• 235000004443 Ricinus communis Nutrition 0.000 description 1
• 102100030852 Run domain Beclin-1-interacting and cysteine-rich domain-containing protein Human genes 0.000 description 1
• 101150036449 SIRPA gene Proteins 0.000 description 1
• AUVVAXYIELKVAI-UHFFFAOYSA-N SJ000285215 Natural products N1CCC2=CC(OC)=C(OC)C=C2C1CC1CC2C3=CC(OC)=C(OC)C=C3CCN2CC1CC AUVVAXYIELKVAI-UHFFFAOYSA-N 0.000 description 1
• 208000004337 Salivary Gland Neoplasms Diseases 0.000 description 1
• 206010039915 Selective IgA immunodeficiency Diseases 0.000 description 1
• QMCDMHWAKMUGJE-IHRRRGAJSA-N Ser-Phe-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(O)=O QMCDMHWAKMUGJE-IHRRRGAJSA-N 0.000 description 1
• RTXKJFWHEBTABY-IHPCNDPISA-N Ser-Trp-Tyr Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)O)NC(=O)[C@H](CO)N RTXKJFWHEBTABY-IHPCNDPISA-N 0.000 description 1
• 102100034361 Sialic acid-binding Ig-like lectin 15 Human genes 0.000 description 1
• 102100029964 Sialic acid-binding Ig-like lectin 8 Human genes 0.000 description 1
• 102100029965 Sialic acid-binding Ig-like lectin 9 Human genes 0.000 description 1
• DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
• DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
• 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
• 240000003768 Solanum lycopersicum Species 0.000 description 1
• 235000002595 Solanum tuberosum Nutrition 0.000 description 1
• 244000061456 Solanum tuberosum Species 0.000 description 1
• 238000002105 Southern blotting Methods 0.000 description 1
• SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
• 108010090804 Streptavidin Proteins 0.000 description 1
• 229920006328 Styrofoam Polymers 0.000 description 1
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
• 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
• RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
• 208000024770 Thyroid neoplasm Diseases 0.000 description 1
• 102000008236 Toll-Like Receptor 7 Human genes 0.000 description 1
• 108010060825 Toll-Like Receptor 7 Proteins 0.000 description 1
• 102000008208 Toll-Like Receptor 8 Human genes 0.000 description 1
• 108010060752 Toll-Like Receptor 8 Proteins 0.000 description 1
• 229920001615 Tragacanth Polymers 0.000 description 1
• 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
• 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
• 239000007983 Tris buffer Substances 0.000 description 1
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
• ARJASMXQBRNAGI-YESZJQIVSA-N Tyr-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)N ARJASMXQBRNAGI-YESZJQIVSA-N 0.000 description 1
• 102100029948 Tyrosine-protein phosphatase non-receptor type substrate 1 Human genes 0.000 description 1
• GBOGMAARMMDZGR-UHFFFAOYSA-N UNPD149280 Natural products N1C(=O)C23OC(=O)C=CC(O)CCCC(C)CC=CC3C(O)C(=C)C(C)C2C1CC1=CC=CC=C1 GBOGMAARMMDZGR-UHFFFAOYSA-N 0.000 description 1
• 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 description 1
• 208000023915 Ureteral Neoplasms Diseases 0.000 description 1
• 206010046458 Urethral neoplasms Diseases 0.000 description 1
• 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
• 201000005969 Uveal melanoma Diseases 0.000 description 1
• 101150117115 V gene Proteins 0.000 description 1
• PAPWZOJOLKZEFR-AVGNSLFASA-N Val-Arg-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)O)N PAPWZOJOLKZEFR-AVGNSLFASA-N 0.000 description 1
• 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
• JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
• 206010047741 Vulval cancer Diseases 0.000 description 1
• 208000004354 Vulvar Neoplasms Diseases 0.000 description 1
• 240000008042 Zea mays Species 0.000 description 1
• 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
• 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
• ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 1
• 239000002250 absorbent Substances 0.000 description 1
• 230000002745 absorbent Effects 0.000 description 1
• 239000003655 absorption accelerator Substances 0.000 description 1
• 239000008351 acetate buffer Substances 0.000 description 1
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
• RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
• 239000012190 activator Substances 0.000 description 1
• 239000004480 active ingredient Substances 0.000 description 1
• 239000013543 active substance Substances 0.000 description 1
• 230000002411 adverse Effects 0.000 description 1
• 235000010419 agar Nutrition 0.000 description 1
• 230000002776 aggregation Effects 0.000 description 1
• 238000004220 aggregation Methods 0.000 description 1
• 108010024078 alanyl-glycyl-serine Proteins 0.000 description 1
• 239000000783 alginic acid Substances 0.000 description 1
• 229960001126 alginic acid Drugs 0.000 description 1
• 150000004781 alginic acids Chemical class 0.000 description 1
• 229910001508 alkali metal halide Inorganic materials 0.000 description 1
• 150000008045 alkali metal halides Chemical class 0.000 description 1
• 108010029483 alpha 1 Chain Collagen Type I Proteins 0.000 description 1
• AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
• 230000004075 alteration Effects 0.000 description 1
• 229920005603 alternating copolymer Polymers 0.000 description 1
• 235000012211 aluminium silicate Nutrition 0.000 description 1
• 230000001668 ameliorated effect Effects 0.000 description 1
• 150000001412 amines Chemical class 0.000 description 1
• 125000003277 amino group Chemical group 0.000 description 1
• 229910021529 ammonia Inorganic materials 0.000 description 1
• BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
• 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
• 239000001166 ammonium sulphate Substances 0.000 description 1
• 235000011130 ammonium sulphate Nutrition 0.000 description 1
• 210000004102 animal cell Anatomy 0.000 description 1
• MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 1
• 230000009833 antibody interaction Effects 0.000 description 1
• 102000025171 antigen binding proteins Human genes 0.000 description 1
• 108091000831 antigen binding proteins Proteins 0.000 description 1
• 230000009831 antigen interaction Effects 0.000 description 1
• 210000000612 antigen-presenting cell Anatomy 0.000 description 1
• 239000004599 antimicrobial Substances 0.000 description 1
• 239000002246 antineoplastic agent Substances 0.000 description 1
• 239000003963 antioxidant agent Substances 0.000 description 1
• 235000006708 antioxidants Nutrition 0.000 description 1
• 229940027983 antiseptic and disinfectant quaternary ammonium compound Drugs 0.000 description 1
• 238000013459 approach Methods 0.000 description 1
• 235000010323 ascorbic acid Nutrition 0.000 description 1
• 239000011668 ascorbic acid Substances 0.000 description 1
• 229960005070 ascorbic acid Drugs 0.000 description 1
• 235000003704 aspartic acid Nutrition 0.000 description 1
• 210000003719 b-lymphocyte Anatomy 0.000 description 1
• 239000000440 bentonite Substances 0.000 description 1
• 229910000278 bentonite Inorganic materials 0.000 description 1
• SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
• 229960000686 benzalkonium chloride Drugs 0.000 description 1
• 235000010233 benzoic acid Nutrition 0.000 description 1
• 229960004365 benzoic acid Drugs 0.000 description 1
• 229960002903 benzyl benzoate Drugs 0.000 description 1
• CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
• OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
• WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
• 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
• 229960004853 betadex Drugs 0.000 description 1
• 239000011230 binding agent Substances 0.000 description 1
• 230000003115 biocidal effect Effects 0.000 description 1
• 229920001400 block copolymer Polymers 0.000 description 1
• RSIHSRDYCUFFLA-DYKIIFRCSA-N boldenone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 RSIHSRDYCUFFLA-DYKIIFRCSA-N 0.000 description 1
• 230000037180 bone health Effects 0.000 description 1
• 210000000133 brain stem Anatomy 0.000 description 1
• 210000000481 breast Anatomy 0.000 description 1
• 201000005389 breast carcinoma in situ Diseases 0.000 description 1
• 201000002143 bronchus adenoma Diseases 0.000 description 1
• 239000006172 buffering agent Substances 0.000 description 1
• 239000004067 bulking agent Substances 0.000 description 1
• 235000019437 butane-1,3-diol Nutrition 0.000 description 1
• 239000006227 byproduct Substances 0.000 description 1
• 229960001948 caffeine Drugs 0.000 description 1
• VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
• 239000011575 calcium Substances 0.000 description 1
• 229910052791 calcium Inorganic materials 0.000 description 1
• 229910000019 calcium carbonate Inorganic materials 0.000 description 1
• 235000010216 calcium carbonate Nutrition 0.000 description 1
• 239000001506 calcium phosphate Substances 0.000 description 1
• CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
• 239000008116 calcium stearate Substances 0.000 description 1
• 235000013539 calcium stearate Nutrition 0.000 description 1
• 235000014633 carbohydrates Nutrition 0.000 description 1
• 239000001569 carbon dioxide Substances 0.000 description 1
• 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
• 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
• 239000004359 castor oil Substances 0.000 description 1
• 230000022534 cell killing Effects 0.000 description 1
• 210000003855 cell nucleus Anatomy 0.000 description 1
• 239000001913 cellulose Substances 0.000 description 1
• 235000010980 cellulose Nutrition 0.000 description 1
• 229920002678 cellulose Polymers 0.000 description 1
• 210000003169 central nervous system Anatomy 0.000 description 1
• 238000005119 centrifugation Methods 0.000 description 1
• 201000007335 cerebellar astrocytoma Diseases 0.000 description 1
• 208000030239 cerebral astrocytoma Diseases 0.000 description 1
• 230000002490 cerebral effect Effects 0.000 description 1
• 229930183167 cerebroside Natural products 0.000 description 1
• 150000001784 cerebrosides Chemical class 0.000 description 1
• 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
• 201000010881 cervical cancer Diseases 0.000 description 1
• 229960000541 cetyl alcohol Drugs 0.000 description 1
• 239000002738 chelating agent Substances 0.000 description 1
• NDAYQJDHGXTBJL-MWWSRJDJSA-N chembl557217 Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](NC(=O)CNC(=O)[C@@H](NC=O)C(C)C)CC(C)C)C(=O)NCCO)=CNC2=C1 NDAYQJDHGXTBJL-MWWSRJDJSA-N 0.000 description 1
• 239000003153 chemical reaction reagent Substances 0.000 description 1
• 238000002512 chemotherapy Methods 0.000 description 1
• 229960003260 chlorhexidine Drugs 0.000 description 1
• 235000012000 cholesterol Nutrition 0.000 description 1
• 229940107161 cholesterol Drugs 0.000 description 1
• 210000000349 chromosome Anatomy 0.000 description 1
• 230000001684 chronic effect Effects 0.000 description 1
• 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
• 150000001860 citric acid derivatives Chemical class 0.000 description 1
• 239000004927 clay Substances 0.000 description 1
• 230000009194 climbing Effects 0.000 description 1
• 230000007012 clinical effect Effects 0.000 description 1
• 238000011260 co-administration Methods 0.000 description 1
• 229960001338 colchicine Drugs 0.000 description 1
• 210000001072 colon Anatomy 0.000 description 1
• 208000029742 colonic neoplasm Diseases 0.000 description 1
• 208000011588 combined hepatocellular carcinoma and cholangiocarcinoma Diseases 0.000 description 1
• 230000001447 compensatory effect Effects 0.000 description 1
• 239000008139 complexing agent Substances 0.000 description 1
• 238000013329 compounding Methods 0.000 description 1
• 238000004590 computer program Methods 0.000 description 1
• 208000029192 congenital agammaglobulinemia Diseases 0.000 description 1
• 239000000562 conjugate Substances 0.000 description 1
• 230000001276 controlling effect Effects 0.000 description 1
• 229920001577 copolymer Polymers 0.000 description 1
• 235000005822 corn Nutrition 0.000 description 1
• 230000001054 cortical effect Effects 0.000 description 1
• 239000003246 corticosteroid Substances 0.000 description 1
• 235000012343 cottonseed oil Nutrition 0.000 description 1
• 210000004748 cultured cell Anatomy 0.000 description 1
• 238000009109 curative therapy Methods 0.000 description 1
• 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
• 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
• 229960003067 cystine Drugs 0.000 description 1
• GBOGMAARMMDZGR-TYHYBEHESA-N cytochalasin B Chemical compound C([C@H]1[C@@H]2[C@@H](C([C@@H](O)[C@@H]3/C=C/C[C@H](C)CCC[C@@H](O)/C=C/C(=O)O[C@@]23C(=O)N1)=C)C)C1=CC=CC=C1 GBOGMAARMMDZGR-TYHYBEHESA-N 0.000 description 1
• GBOGMAARMMDZGR-JREHFAHYSA-N cytochalasin B Natural products C[C@H]1CCC[C@@H](O)C=CC(=O)O[C@@]23[C@H](C=CC1)[C@H](O)C(=C)[C@@H](C)[C@@H]2[C@H](Cc4ccccc4)NC3=O GBOGMAARMMDZGR-JREHFAHYSA-N 0.000 description 1
• 229940127089 cytotoxic agent Drugs 0.000 description 1
• 238000011393 cytotoxic chemotherapy Methods 0.000 description 1
• 229960000640 dactinomycin Drugs 0.000 description 1
• 229960000975 daunorubicin Drugs 0.000 description 1
• STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
• RSIHSRDYCUFFLA-UHFFFAOYSA-N dehydrotestosterone Natural products O=C1C=CC2(C)C3CCC(C)(C(CC4)O)C4C3CCC2=C1 RSIHSRDYCUFFLA-UHFFFAOYSA-N 0.000 description 1
• CFCUWKMKBJTWLW-UHFFFAOYSA-N deoliosyl-3C-alpha-L-digitoxosyl-MTM Natural products CC=1C(O)=C2C(O)=C3C(=O)C(OC4OC(C)C(O)C(OC5OC(C)C(O)C(OC6OC(C)C(O)C(C)(O)C6)C5)C4)C(C(OC)C(=O)C(O)C(C)O)CC3=CC2=CC=1OC(OC(C)C1O)CC1OC1CC(O)C(O)C(C)O1 CFCUWKMKBJTWLW-UHFFFAOYSA-N 0.000 description 1
• 230000001419 dependent effect Effects 0.000 description 1
• 238000009795 derivation Methods 0.000 description 1
• 238000013461 design Methods 0.000 description 1
• 235000019425 dextrin Nutrition 0.000 description 1
• 239000008121 dextrose Substances 0.000 description 1
• 238000003745 diagnosis Methods 0.000 description 1
• CGMRCMMOCQYHAD-UHFFFAOYSA-J dicalcium hydroxide phosphate Chemical compound [OH-].[Ca++].[Ca++].[O-]P([O-])([O-])=O CGMRCMMOCQYHAD-UHFFFAOYSA-J 0.000 description 1
• NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
• 229940038472 dicalcium phosphate Drugs 0.000 description 1
• 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
• 235000014113 dietary fatty acids Nutrition 0.000 description 1
• 238000009792 diffusion process Methods 0.000 description 1
• 239000000539 dimer Substances 0.000 description 1
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
• 150000002016 disaccharides Chemical class 0.000 description 1
• 230000005750 disease progression Effects 0.000 description 1
• 238000004090 dissolution Methods 0.000 description 1
• 239000012153 distilled water Substances 0.000 description 1
• NAGJZTKCGNOGPW-UHFFFAOYSA-N dithiophosphoric acid Chemical class OP(O)(S)=S NAGJZTKCGNOGPW-UHFFFAOYSA-N 0.000 description 1
• 231100000673 dose–response relationship Toxicity 0.000 description 1
• 230000003828 downregulation Effects 0.000 description 1
• 229960004679 doxorubicin Drugs 0.000 description 1
• 239000008298 dragée Substances 0.000 description 1
• 229940079593 drug Drugs 0.000 description 1
• 238000009547 dual-energy X-ray absorptiometry Methods 0.000 description 1
• 208000028715 ductal breast carcinoma in situ Diseases 0.000 description 1
• 201000007273 ductal carcinoma in situ Diseases 0.000 description 1
• 239000000975 dye Substances 0.000 description 1
• AUVVAXYIELKVAI-CKBKHPSWSA-N emetine Chemical compound N1CCC2=CC(OC)=C(OC)C=C2[C@H]1C[C@H]1C[C@H]2C3=CC(OC)=C(OC)C=C3CCN2C[C@@H]1CC AUVVAXYIELKVAI-CKBKHPSWSA-N 0.000 description 1
• 229960002694 emetine Drugs 0.000 description 1
• AUVVAXYIELKVAI-UWBTVBNJSA-N emetine Natural products N1CCC2=CC(OC)=C(OC)C=C2[C@H]1C[C@H]1C[C@H]2C3=CC(OC)=C(OC)C=C3CCN2C[C@H]1CC AUVVAXYIELKVAI-UWBTVBNJSA-N 0.000 description 1
• 230000001804 emulsifying effect Effects 0.000 description 1
• 230000002357 endometrial effect Effects 0.000 description 1
• 230000002708 enhancing effect Effects 0.000 description 1
• 235000019441 ethanol Nutrition 0.000 description 1
• BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
• ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
• 229960005542 ethidium bromide Drugs 0.000 description 1
• 229940093499 ethyl acetate Drugs 0.000 description 1
• VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
• 229960005420 etoposide Drugs 0.000 description 1
• 238000011156 evaluation Methods 0.000 description 1
• 210000001508 eye Anatomy 0.000 description 1
• 208000024519 eye neoplasm Diseases 0.000 description 1
• 239000003925 fat Substances 0.000 description 1
• 235000019197 fats Nutrition 0.000 description 1
• 239000000194 fatty acid Substances 0.000 description 1
• 229930195729 fatty acid Natural products 0.000 description 1
• MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
• 239000003205 fragrance Substances 0.000 description 1
• UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 1
• 210000000232 gallbladder Anatomy 0.000 description 1
• 108010044804 gamma-glutamyl-seryl-glycine Proteins 0.000 description 1
• 108010063718 gamma-glutamylaspartic acid Proteins 0.000 description 1
• 150000002270 gangliosides Chemical class 0.000 description 1
• 230000002496 gastric effect Effects 0.000 description 1
• 238000001502 gel electrophoresis Methods 0.000 description 1
• 239000007903 gelatin capsule Substances 0.000 description 1
• 238000002523 gelfiltration Methods 0.000 description 1
• 238000001415 gene therapy Methods 0.000 description 1
• 230000002068 genetic effect Effects 0.000 description 1
• 235000013922 glutamic acid Nutrition 0.000 description 1
• 239000004220 glutamic acid Substances 0.000 description 1
• YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
• SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
• 230000002414 glycolytic effect Effects 0.000 description 1
• 229920000578 graft copolymer Polymers 0.000 description 1
• 239000008187 granular material Substances 0.000 description 1
• 230000012010 growth Effects 0.000 description 1
• 229940093915 gynecological organic acid Drugs 0.000 description 1
• 201000009277 hairy cell leukemia Diseases 0.000 description 1
• 210000003128 head Anatomy 0.000 description 1
• 201000010536 head and neck cancer Diseases 0.000 description 1
• 238000003505 heat denaturation Methods 0.000 description 1
• 229960002897 heparin Drugs 0.000 description 1
• 229920000669 heparin Polymers 0.000 description 1
• 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
• 239000000833 heterodimer Substances 0.000 description 1
• 238000005734 heterodimerization reaction Methods 0.000 description 1
• BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
• 230000013632 homeostatic process Effects 0.000 description 1
• 239000000710 homodimer Substances 0.000 description 1
• 229920001519 homopolymer Polymers 0.000 description 1
• 239000003906 humectant Substances 0.000 description 1
• 229910052739 hydrogen Inorganic materials 0.000 description 1
• 239000001257 hydrogen Substances 0.000 description 1
• 229960002163 hydrogen peroxide Drugs 0.000 description 1
• 229920001477 hydrophilic polymer Polymers 0.000 description 1
• 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
• 125000001841 imino group Chemical group [H]N=* 0.000 description 1
• 210000002865 immune cell Anatomy 0.000 description 1
• 238000002649 immunization Methods 0.000 description 1
• 230000005847 immunogenicity Effects 0.000 description 1
• 201000007156 immunoglobulin alpha deficiency Diseases 0.000 description 1
• 230000016784 immunoglobulin production Effects 0.000 description 1
• 229940072221 immunoglobulins Drugs 0.000 description 1
• 238000001114 immunoprecipitation Methods 0.000 description 1
• 239000003018 immunosuppressive agent Substances 0.000 description 1
• 229940124589 immunosuppressive drug Drugs 0.000 description 1
• 230000001976 improved effect Effects 0.000 description 1
• 230000001939 inductive effect Effects 0.000 description 1
• 230000036512 infertility Effects 0.000 description 1
• 230000008595 infiltration Effects 0.000 description 1
• 238000001764 infiltration Methods 0.000 description 1
• 229910052500 inorganic mineral Inorganic materials 0.000 description 1
• 238000003780 insertion Methods 0.000 description 1
• 230000037431 insertion Effects 0.000 description 1
• 230000003434 inspiratory effect Effects 0.000 description 1
• 230000002452 interceptive effect Effects 0.000 description 1
• 108010074109 interleukin-22 Proteins 0.000 description 1
• 238000001361 intraarterial administration Methods 0.000 description 1
• 238000000185 intracerebroventricular administration Methods 0.000 description 1
• 201000007450 intrahepatic cholangiocarcinoma Diseases 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 201000008893 intraocular retinoblastoma Diseases 0.000 description 1
• 238000007913 intrathecal administration Methods 0.000 description 1
• 238000001990 intravenous administration Methods 0.000 description 1
• 238000007914 intraventricular administration Methods 0.000 description 1
• 206010073095 invasive ductal breast carcinoma Diseases 0.000 description 1
• 201000010985 invasive ductal carcinoma Diseases 0.000 description 1
• 206010073096 invasive lobular breast carcinoma Diseases 0.000 description 1
• 238000005342 ion exchange Methods 0.000 description 1
• 150000002500 ions Chemical class 0.000 description 1
• 238000001155 isoelectric focusing Methods 0.000 description 1
• 238000002955 isolation Methods 0.000 description 1
• FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
• 239000000644 isotonic solution Substances 0.000 description 1
• 238000005304 joining Methods 0.000 description 1
• NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
• 239000003410 keratolytic agent Substances 0.000 description 1
• 210000003734 kidney Anatomy 0.000 description 1
• 210000000244 kidney pelvis Anatomy 0.000 description 1
• 229940043355 kinase inhibitor Drugs 0.000 description 1
• 238000002372 labelling Methods 0.000 description 1
• 238000011005 laboratory method Methods 0.000 description 1
• 229910052747 lanthanoid Inorganic materials 0.000 description 1
• 150000002602 lanthanoids Chemical class 0.000 description 1
• 239000000787 lecithin Substances 0.000 description 1
• 235000010445 lecithin Nutrition 0.000 description 1
• 229940067606 lecithin Drugs 0.000 description 1
• 231100000518 lethal Toxicity 0.000 description 1
• 230000001665 lethal effect Effects 0.000 description 1
• 229960004194 lidocaine Drugs 0.000 description 1
• 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
• 235000019421 lipase Nutrition 0.000 description 1
• 201000011059 lobular neoplasia Diseases 0.000 description 1
• 239000006210 lotion Substances 0.000 description 1
• 239000000314 lubricant Substances 0.000 description 1
• 210000004072 lung Anatomy 0.000 description 1
• 208000025036 lymphosarcoma Diseases 0.000 description 1
• 239000011777 magnesium Substances 0.000 description 1
• 229910052749 magnesium Inorganic materials 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• 238000002595 magnetic resonance imaging Methods 0.000 description 1
• 238000012423 maintenance Methods 0.000 description 1
• 230000036210 malignancy Effects 0.000 description 1
• 208000030883 malignant astrocytoma Diseases 0.000 description 1
• 208000020984 malignant renal pelvis neoplasm Diseases 0.000 description 1
• 208000026037 malignant tumor of neck Diseases 0.000 description 1
• 239000011159 matrix material Substances 0.000 description 1
• 230000007246 mechanism Effects 0.000 description 1
• 238000002844 melting Methods 0.000 description 1
• 230000008018 melting Effects 0.000 description 1
• 210000000716 merkel cell Anatomy 0.000 description 1
• 210000003716 mesoderm Anatomy 0.000 description 1
• MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
• 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
• 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
• 229960002216 methylparaben Drugs 0.000 description 1
• YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical class CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
• 239000004530 micro-emulsion Substances 0.000 description 1
• 239000011859 microparticle Substances 0.000 description 1
• 239000004005 microsphere Substances 0.000 description 1
• 235000013336 milk Nutrition 0.000 description 1
• 239000008267 milk Substances 0.000 description 1
• 210000004080 milk Anatomy 0.000 description 1
• 235000010755 mineral Nutrition 0.000 description 1
• 239000011707 mineral Substances 0.000 description 1
• CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
• 229960004857 mitomycin Drugs 0.000 description 1
• 229960001156 mitoxantrone Drugs 0.000 description 1
• KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
• 150000002772 monosaccharides Chemical class 0.000 description 1
• 238000010172 mouse model Methods 0.000 description 1
• 201000005962 mycosis fungoides Diseases 0.000 description 1
• 201000000050 myeloid neoplasm Diseases 0.000 description 1
• 208000010125 myocardial infarction Diseases 0.000 description 1
• 239000002088 nanocapsule Substances 0.000 description 1
• 210000003739 neck Anatomy 0.000 description 1
• 230000007935 neutral effect Effects 0.000 description 1
• 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
• 238000007899 nucleic acid hybridization Methods 0.000 description 1
• 201000002575 ocular melanoma Diseases 0.000 description 1
• 239000004006 olive oil Substances 0.000 description 1
• 230000003287 optical effect Effects 0.000 description 1
• 150000007524 organic acids Chemical class 0.000 description 1
• 235000005985 organic acids Nutrition 0.000 description 1
• 208000005368 osteomalacia Diseases 0.000 description 1
• 230000002611 ovarian Effects 0.000 description 1
• 230000003647 oxidation Effects 0.000 description 1
• 238000007254 oxidation reaction Methods 0.000 description 1
• 239000005022 packaging material Substances 0.000 description 1
• 229960001592 paclitaxel Drugs 0.000 description 1
• 238000002638 palliative care Methods 0.000 description 1
• 229940055729 papain Drugs 0.000 description 1
• 235000019834 papain Nutrition 0.000 description 1
• 239000012188 paraffin wax Substances 0.000 description 1
• 230000000849 parathyroid Effects 0.000 description 1
• 230000036961 partial effect Effects 0.000 description 1
• 230000001575 pathological effect Effects 0.000 description 1
• 230000007170 pathology Effects 0.000 description 1
• 230000037361 pathway Effects 0.000 description 1
• 229940111202 pepsin Drugs 0.000 description 1
• 238000010647 peptide synthesis reaction Methods 0.000 description 1
• 239000002304 perfume Substances 0.000 description 1
• 230000002093 peripheral effect Effects 0.000 description 1
• 230000003285 pharmacodynamic effect Effects 0.000 description 1
• 230000009038 pharmacological inhibition Effects 0.000 description 1
• WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
• 235000021317 phosphate Nutrition 0.000 description 1
• 125000001095 phosphatidyl group Chemical group 0.000 description 1
• 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
• 150000003904 phospholipids Chemical class 0.000 description 1
• 150000008298 phosphoramidates Chemical class 0.000 description 1
• 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
• 230000026731 phosphorylation Effects 0.000 description 1
• 238000006366 phosphorylation reaction Methods 0.000 description 1
• 102000020233 phosphotransferase Human genes 0.000 description 1
• 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
• 230000036314 physical performance Effects 0.000 description 1
• 239000002504 physiological saline solution Substances 0.000 description 1
• 208000024724 pineal body neoplasm Diseases 0.000 description 1
• 230000036470 plasma concentration Effects 0.000 description 1
• 229960003171 plicamycin Drugs 0.000 description 1
• 229920001983 poloxamer Polymers 0.000 description 1
• 230000008488 polyadenylation Effects 0.000 description 1
• 238000006116 polymerization reaction Methods 0.000 description 1
• 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
• 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
• 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
• 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
• 210000004896 polypeptide structure Anatomy 0.000 description 1
• 229920001296 polysiloxane Polymers 0.000 description 1
• 229920000136 polysorbate Polymers 0.000 description 1
• 229940068977 polysorbate 20 Drugs 0.000 description 1
• 229940068968 polysorbate 80 Drugs 0.000 description 1
• 229920000053 polysorbate 80 Polymers 0.000 description 1
• 229940068965 polysorbates Drugs 0.000 description 1
• 230000004481 post-translational protein modification Effects 0.000 description 1
• 239000011591 potassium Substances 0.000 description 1
• 229910052700 potassium Inorganic materials 0.000 description 1
• 239000001103 potassium chloride Substances 0.000 description 1
• 235000011164 potassium chloride Nutrition 0.000 description 1
• 238000001556 precipitation Methods 0.000 description 1
• 230000002265 prevention Effects 0.000 description 1
• 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
• 208000028529 primary immunodeficiency disease Diseases 0.000 description 1
• 208000029340 primitive neuroectodermal tumor Diseases 0.000 description 1
• 229960004919 procaine Drugs 0.000 description 1
• MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
• 238000004393 prognosis Methods 0.000 description 1
• 230000000750 progressive effect Effects 0.000 description 1
• 230000009465 prokaryotic expression Effects 0.000 description 1
• 230000001737 promoting effect Effects 0.000 description 1
• 239000003380 propellant Substances 0.000 description 1
• 229960003712 propranolol Drugs 0.000 description 1
• 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
• 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
• 235000013772 propylene glycol Nutrition 0.000 description 1
• 229960003415 propylparaben Drugs 0.000 description 1
• 210000002307 prostate Anatomy 0.000 description 1
• 235000019833 protease Nutrition 0.000 description 1
• 238000000159 protein binding assay Methods 0.000 description 1
• 108020001580 protein domains Proteins 0.000 description 1
• 238000001742 protein purification Methods 0.000 description 1
• 230000017854 proteolysis Effects 0.000 description 1
• 230000002797 proteolythic effect Effects 0.000 description 1
• 230000005180 public health Effects 0.000 description 1
• 208000002815 pulmonary hypertension Diseases 0.000 description 1
• 229950010131 puromycin Drugs 0.000 description 1
• HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
• 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
• 230000005855 radiation Effects 0.000 description 1
• 150000003254 radicals Chemical class 0.000 description 1
• 229920005604 random copolymer Polymers 0.000 description 1
• 239000011541 reaction mixture Substances 0.000 description 1
• 201000007444 renal pelvis carcinoma Diseases 0.000 description 1
• 210000003019 respiratory muscle Anatomy 0.000 description 1
• 108091008146 restriction endonucleases Proteins 0.000 description 1
• 230000000717 retained effect Effects 0.000 description 1
• 239000003340 retarding agent Substances 0.000 description 1
• 230000001177 retroviral effect Effects 0.000 description 1
• 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
• PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
• 239000002336 ribonucleotide Substances 0.000 description 1
• 210000003705 ribosome Anatomy 0.000 description 1
• 229920002477 rna polymer Polymers 0.000 description 1
• 230000028327 secretion Effects 0.000 description 1
• 208000029138 selective IgA deficiency disease Diseases 0.000 description 1
• 210000002966 serum Anatomy 0.000 description 1
• 239000008159 sesame oil Substances 0.000 description 1
• 235000011803 sesame oil Nutrition 0.000 description 1
• 150000004760 silicates Chemical class 0.000 description 1
• 238000009097 single-agent therapy Methods 0.000 description 1
• 238000002741 site-directed mutagenesis Methods 0.000 description 1
• 238000001542 size-exclusion chromatography Methods 0.000 description 1
• 201000000849 skin cancer Diseases 0.000 description 1
• 201000008261 skin carcinoma Diseases 0.000 description 1
• 208000000587 small cell lung carcinoma Diseases 0.000 description 1
• 210000000813 small intestine Anatomy 0.000 description 1
• 201000002314 small intestine cancer Diseases 0.000 description 1
• 150000003384 small molecules Chemical class 0.000 description 1
• 229910000029 sodium carbonate Inorganic materials 0.000 description 1
• 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
• 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
• 239000001509 sodium citrate Substances 0.000 description 1
• NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
• 229940079827 sodium hydrogen sulfite Drugs 0.000 description 1
• 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
• 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
• 229940001482 sodium sulfite Drugs 0.000 description 1
• 235000010265 sodium sulphite Nutrition 0.000 description 1
• 239000007787 solid Substances 0.000 description 1
• 239000008247 solid mixture Substances 0.000 description 1
• 235000010199 sorbic acid Nutrition 0.000 description 1
• 239000004334 sorbic acid Substances 0.000 description 1
• 229940075582 sorbic acid Drugs 0.000 description 1
• 238000001179 sorption measurement Methods 0.000 description 1
• 230000009870 specific binding Effects 0.000 description 1
• 150000003408 sphingolipids Chemical class 0.000 description 1
• 210000000952 spleen Anatomy 0.000 description 1
• 239000007921 spray Substances 0.000 description 1
• 206010041823 squamous cell carcinoma Diseases 0.000 description 1
• 230000000087 stabilizing effect Effects 0.000 description 1
• 238000010561 standard procedure Methods 0.000 description 1
• 238000007619 statistical method Methods 0.000 description 1
• 238000003860 storage Methods 0.000 description 1
• 210000000434 stratum corneum Anatomy 0.000 description 1
• 239000008261 styrofoam Substances 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• 238000010254 subcutaneous injection Methods 0.000 description 1
• 239000007929 subcutaneous injection Substances 0.000 description 1
• 235000000346 sugar Nutrition 0.000 description 1
• 150000005846 sugar alcohols Chemical class 0.000 description 1
• 150000008163 sugars Chemical class 0.000 description 1
• 239000011593 sulfur Substances 0.000 description 1
• 229910052717 sulfur Inorganic materials 0.000 description 1
• 230000008093 supporting effect Effects 0.000 description 1
• 238000004114 suspension culture Methods 0.000 description 1
• 238000013268 sustained release Methods 0.000 description 1
• 239000012730 sustained-release form Substances 0.000 description 1
• 239000003765 sweetening agent Substances 0.000 description 1
• 230000002194 synthesizing effect Effects 0.000 description 1
• 239000006188 syrup Substances 0.000 description 1
• 235000020357 syrup Nutrition 0.000 description 1
• 229940037128 systemic glucocorticoids Drugs 0.000 description 1
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
• 230000002123 temporal effect Effects 0.000 description 1
• NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
• 229960001278 teniposide Drugs 0.000 description 1
• 229920001897 terpolymer Polymers 0.000 description 1
• 229960002372 tetracaine Drugs 0.000 description 1
• GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 1
• 238000011285 therapeutic regimen Methods 0.000 description 1
• RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
• 229940033663 thimerosal Drugs 0.000 description 1
• 125000003396 thiol group Chemical group [H]S* 0.000 description 1
• 201000002510 thyroid cancer Diseases 0.000 description 1
• 210000001685 thyroid gland Anatomy 0.000 description 1
• 239000012443 tonicity enhancing agent Substances 0.000 description 1
• 238000011200 topical administration Methods 0.000 description 1
• 239000012049 topical pharmaceutical composition Substances 0.000 description 1
• 235000010487 tragacanth Nutrition 0.000 description 1
• 239000000196 tragacanth Substances 0.000 description 1
• 229940116362 tragacanth Drugs 0.000 description 1
• 230000002103 transcriptional effect Effects 0.000 description 1
• 238000001890 transfection Methods 0.000 description 1
• 230000009466 transformation Effects 0.000 description 1
• 230000010474 transient expression Effects 0.000 description 1
• ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 1
• GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
• 229960000281 trometamol Drugs 0.000 description 1
• 230000004614 tumor growth Effects 0.000 description 1
• 241001430294 unidentified retrovirus Species 0.000 description 1
• 238000011144 upstream manufacturing Methods 0.000 description 1
• 210000000626 ureter Anatomy 0.000 description 1
• 210000004291 uterus Anatomy 0.000 description 1
• 206010046885 vaginal cancer Diseases 0.000 description 1
• 208000013139 vaginal neoplasm Diseases 0.000 description 1
• 235000019871 vegetable fat Nutrition 0.000 description 1
• 229960003048 vinblastine Drugs 0.000 description 1
• JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
• OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
• 229960004528 vincristine Drugs 0.000 description 1
• OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
• 239000013603 viral vector Substances 0.000 description 1
• 201000005102 vulva cancer Diseases 0.000 description 1
• 239000008215 water for injection Substances 0.000 description 1
• 239000011787 zinc oxide Substances 0.000 description 1
• 235000014692 zinc oxide Nutrition 0.000 description 1